Ciclesonide

Catalog No.S4646 Batch:S464603

Print

Technical Data

Formula

C32H44O7
Molecular Weight 540.69 CAS No. 126544-47-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (184.94 mM)
Water Insoluble
 
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Ciclesonide (Alvesco, Omnaris, RPR251526, Zetonna) is a glucocorticoid used to treat obstructive airway diseases.
In vitro Ciclesonide is effectively taken up into human alveolar type II epithelial (A549) cells and metabolized to its pharmacologically active metabolite des-CIC and fatty acid conjugates of desCIC.

Protocol (from reference)

Cell Assay:[2]
  • Cell lines

    Human alveolar type II epithelial cells (A549).

  • Concentrations

    0.02 μM

  • Incubation Time

    1 h

  • Method

    Metabolism of ciclesonide: After initial cultivation, A549 cells are washed five times with 10 ml/dish sterile PBS. An ethanolic stock solution of ciclesonide is diluted 1000-fold with assay medium to generate the initial ciclesonide concentration. The cells are incubated for 1 h in DMEM/0.1% (w/v) BSA (5 ml/dish) containing 0.02μM ciclesonide as described above in a CO2 incubator. At the end of the incubation period, dishes are washed five times with PBS and incubated for 3, 6, or 24 h at the same conditions in 5 ml/dish fresh medium (DMEM/0.1% (w/v) BSA). At each indicated time point, the medium is removed by aspiration, 5 mM EDTA-4Na/PBS added and dishes are incubated for further 5 min. The cells are detached from the dishes and harvested. Each dish is washed five times with icechilled PBS.

Animal Study:[1]
  • Animal Models

    Wistar rats

  • Dosages

    0.5 mg/kg

  • Administration

    i.v.

References

  • https://pubmed.ncbi.nlm.nih.gov/17122529/
  • https://pubmed.ncbi.nlm.nih.gov/17900334/

Selleck's Ciclesonide Has Been Cited by 17 Publications

Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells [ Proceedings of the National Academy of Sciences, November 2025, 122(48)] PubMed: 41289394
The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide [ American Journal of Physiology-Lung Cellular and Molecular Physiology, May 1, 2023, L722-L736]
The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide [ American Journal of Physiology-Lung Cellular and Molecular Physiology, May 1, 2023, L722-L736] PubMed: nan
Drug repurposing screen identifies an HRI activating compound that promotes adaptive mitochondrial remodeling in MFN2-deficient cells [ bioRxiv, June 26, 2025, 2025.06.23.660251] PubMed: 41289394
The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b [ Pharmaceutics, July 21, 2022, 1511] PubMed: 35890406
Drug Repurposing Screen Identifies an HRI Activating Compound that Promotes Adaptive Mitochondrial Remodeling in MFN2-deficient Cells [ bioRxiv, 2025, 2025.06.23.660251] PubMed: 40666974
Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinsons disease [ Acta Pharmaceutica Sinica B, 2023, 662-677] PubMed: 36873178
Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease [ Acta Pharm Sin B, 2023, 13(2):662-677] PubMed: 36873178
The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a model of COVID-19 viremia that is rescued by the glucocorticoid ciclesonide [ American Journal of Physiology-Lung Cellular and Molecular Physiology, 2023, L722-L736] PubMed: nan
The Pathophysiology of COVID-19 and SARS-CoV-2 Infection: The SARS-CoV-2 E protein induces Toll-like receptor 2-mediated neonatal lung injury in a [ Am J Physiol Lung Cell Mol Physiol, 2023, 324(5):L722-L736.] PubMed: 36976925

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.